2,4-Dihydro-4-(4-methylphenyl)-3H-1,2,4-triazol-3-one | CAS:93192-57-5
2,4-Dihydro-4-(4-methylphenyl)-3H-1,2,4-triazol-3-one
- 名称:2,4-二氢-4-(4-甲基苯基)-3H-1,2,4-三唑-3-酮 | 2,4-Dihydro-4-(4-methylphenyl)-3H-1,2,4-triazol-3-one
- CAS号:93192-57-5
- 别名:
- 分子式:C9H9N3O
- 分子量:175.19
- EINESC号:
产品描述
物理化学性质
密度 | 1.27±0.1 g/cm3 (20 ºC |
---|
安全数据
没有数据 | 没有数据 |
---|
SDS
来源 | SDS样本 |
---|---|
没有数据 | 没有数据 |
产品合成路线
更多
名称 | CAS号 |
---|
更多
文章
同行评议文献
Comparative study on the effects of some polyoxyethylene alkyl ether and sorbitan fatty acid ester surfactants on the performance of transdermal carvedilol proniosomal gel using experimental design.Ahmed A Aboelwafa et al.AAPS PharmSciTech, 11(4), 1591-1602 (2010-11-11)
An investigation into the role of surfactants in controlling particle size of polymeric nanocapsules containing penicillin-G in double emulsion.Sepideh Khoee et al.European journal of medicinal chemistry, 44(6), 2392-2399 (2008-11-18)
Surfactant-stabilized microbubbles as ultrasound contrast agents: stability study of [TM="Span"] 60 and Tween 80 mixtures using a Langmuir troughSinghal, S., et al. Langmuir, 9, 2426-2426 (1993)
Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid.Varaporn Buraphacheep Junyaprasert et al.International journal of pharmaceutics, 423(2), 303-311 (2011-12-14)
Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation.Amit Rawat et al.Journal of controlled release : official journal of the Controlled Release Society, 128(3), 224-232 (2008-05-13)
Preparation and characterization of molecularly imprinted microspheres for dibutyl phthalate recognition in aqueous environment.Juan He et al.Journal of separation science, 33(21), 3409-3414 (2010-10-12)
Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design.Ajay B Solanki et al.AAPS PharmSciTech, 8(4), E86-E86 (2008-01-10)
Low molecular weight heparin loaded pH-sensitive microparticles.Yvette Meissner et al.International journal of pharmaceutics, 335(1-2), 147-153 (2006-12-08)
Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine.Aline Ferreira Ourique et al.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 79(1), 95-101 (2011-03-16)
Spanlastics--a novel nanovesicular carrier system for ocular delivery.Shilpa Kakkar et al.International journal of pharmaceutics, 413(1-2), 202-210 (2011-05-05)
Fatty alcohols or fatty acids as niosomal hybrid carrier: effect on vesicle size, encapsulation efficiency and in vitro dye release.Prasun Bandyopadhyay et al.Colloids and surfaces. B, Biointerfaces, 58(1), 68-71 (2007-03-07)
Preparation and characterization of niosomes containing ribavirin for liver targeting.Fahima Hashim et al.Drug delivery, 17(5), 282-287 (2010-03-31)
Air-jet and vibrating-mesh nebulization of niosomes generated using a particulate-based proniosome technology.Abdelbary Elhissi et al.International journal of pharmaceutics, 444(1-2), 193-199 (2013-01-10)
Novel ultrasound contrast agent based on microbubbles generated from surfactant mixtures of Span 60 and polyoxyethylene 40 stearate.Zhanwen Xing et al.Acta biomaterialia, 6(9), 3542-3549 (2010-03-17)
Effect of sorbitan monostearate on the physical characteristics and whipping properties of whipped cream.Qiangzhong Zhao et al.Food chemistry, 141(3), 1834-1840 (2013-07-23)
Effects of surfactant characteristics on drug availability from suppositories.N Realdon et al.Die Pharmazie, 63(6), 459-463 (2008-07-09)
Caffeine-loaded niosomes: characterization and in vitro release studies.Payam Khazaeli et al.Drug delivery, 14(7), 447-452 (2007-11-13)
Evidence for vesicle formation from 1:1 nonionic surfactant span 60 and fatty alcohol mixtures in aqueous ethanol: potential delivery vehicle composition.Prasun Bandyopadhyay et al.Colloids and surfaces. B, Biointerfaces, 58(2), 305-308 (2007-04-07)
Design and optimization of surfactant-based nanovesicles for ocular delivery of Clotrimazole.Mona Basha et al.Journal of liposome research, 23(3), 203-210 (2013-04-24)
Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.Ismail A Attia et al.AAPS PharmSciTech, 8(4), E106-E106 (2008-01-10)
Evaluation of the physical stability of two oleogels.Isabel F Almeida et al.International journal of pharmaceutics, 327(1-2), 73-77 (2006-09-26)
In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration.Mohamed Nasr AAPS PharmSciTech, 11(1), 85-89 (2010-01-09)
Preparation of curcuminoid niosomes for enhancement of skin permeation.N Rungphanichkul et al.Die Pharmazie, 66(8), 570-575 (2011-09-10)
Stability of luciferase plasmid entrapped in cationic bilayer vesicles.A Manosroi et al.International journal of pharmaceutics, 356(1-2), 291-299 (2008-02-19)
Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse.I F Uchegbu et al.Pharmaceutical research, 12(7), 1019-1024 (1995-07-01)
The preparation of pellets containing non-ionic surfactants by extrusion/spheronization.F Podczeck et al.International journal of pharmaceutics, 361(1-2), 33-40 (2008-06-24)
Preparation and properties of vesicles (niosomes) of sorbitan monoesters ([TM="Span"] 20, 40, 60 and 80) and a sorbitan triester ([TM="Span"] 85).Yoshioka, T., et al. International Journal of Pharmaceutics, 105, 1-1 (1994)
Studies on nonionic surfactant bilayer vesicles of ciclopirox olamine.Karimunnisa Sameer Shaikh et al.Drug development and industrial pharmacy, 36(8), 946-953 (2010-03-04)
Moisturizing effect of oleogel/hydrogel mixtures.I F Almeida et al.Pharmaceutical development and technology, 13(6), 487-494 (2008-08-23)
[9-nitrocamptothecin nanostructured lipid carrier system: in vitro releasing characteristics, uptake by cells, and tissue distribution in vivo].Jun-chan Li et al.Yao xue xue bao = Acta pharmaceutica Sinica, 40(11), 970-975 (2006-02-28)
备注
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).
名称 | CAS号 |
---|
相关产品
相关资讯
问
热门标签
询 单
请 填 写 相 关 信 息
- 请填写产品名称!
- CAS号
- 请正确填写公司名称!
- 请正确填写联系人!
- 请正确填写联系电话!
- 请正确填写联系邮箱!
- 请描述您的问题!